Related Experiment Video

Updated: Jun 3, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

Claudia Lebedinsky1, Javier Gómez, Youn C Park

  • 1PharmaMar, Colmenar Viejo, Madrid, Spain.

Cancer Chemotherapy and Pharmacology
|March 19, 2011
PubMed

Insights

Trabectedin demonstrates a low incidence of cardiac adverse events (CAEs), primarily arrhythmias, across multiple clinical trials and postmarketing surveillance. This comprehensive review confirms a favorable cardiac safety profile for trabectedin in cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiology

Background:

  • Trabectedin is an anti-cancer drug used in treating various malignancies.
  • Cardiac adverse events (CAEs) are a potential concern with chemotherapeutic agents.
  • Evaluating the cardiac safety profile of trabectedin is crucial for its clinical application.

Purpose of the Study:

  • To conduct a cross-study evaluation of the cardiac safety of trabectedin.
  • To assess the incidence and nature of drug-related cardiac adverse events (CAEs) associated with trabectedin.
  • To determine the overall cardiac risk profile of trabectedin.

Main Methods:

  • Retrieved drug-related CAEs from phase I-III clinical trials and pharmacovigilance databases.
  • Monitored left ventricular ejection fraction (LVEF) in specific combination trials and a phase III trial.
  • Analyzed data from single-agent and combination studies, including postmarketing surveillance.

Main Results:

  • CAEs occurred in 1.4% to 1.8% of patients across different trial phases.
  • Arrhythmias, such as tachycardia and atrial fibrillation, were the most common CAEs.
  • No clinically relevant LVEF changes were observed in combination trials or the phase III trial.

Conclusions:

  • Trabectedin exhibits a low incidence of cardiac adverse events, predominantly arrhythmias.
  • The overall cardiac risk profile associated with trabectedin is considered low.
  • Extensive data review supports the cardiac safety of trabectedin.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System V: CT01:28

Imaging Studies for Cardiovascular System V: CT

Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).